SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

KENDU CRYPTO is trending due to its exceptionally active and dedicated community, which is relentlessly building a "permissionless brand" through numerous real-world product initiatives and ongoing celebratory events. This strong conviction and resilience are driving significant momentum, showcasing the project's consistent expansion even amidst challenging market conditions.

Fortuna Mining Corp. engages in the exploration, extraction and processing of precious and base metal in Latin America. It operates through the following segments: Minera Bateas S.A.C (Bateas), Compania Minera Cuzcatlan S.A. de C.V. (Cuzcatian), Mansfield Minera S.A. (Mansfield), and Corporate. The Beates segment operates the Caylloma silver, lead, and zinc mine. The Cuzcatlan segment handles the San Jose silver-gold mine. The Mansfield segment constructs the Lindero mine. The Corporate segment represents the corporate stewardship. The company was founded by Jorge Alberto Ganoza Durant, Simon T. P. Ridgway, and Mario David Szotlender on September 4, 1990 and is headquartered in Vancouver, Canada.

Fortuna Mining Corp.

Fortuna Silver Mines Inc.

Fortuna Silver Mines is trending as investors weigh its reported record free cash flow and strategic asset sales against persistent community frustration over its perceived undervaluation and lagging performance, despite a bullish precious metals environment.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circle (CRCL) is a hot topic as the market anticipates clarity from ongoing White House discussions on the CLARITY Act, sparking intense community debate around stablecoin regulation, the ability to offer yields, and its pivotal role as digital financial infrastructure amid broader crypto market sentiment.

Bitcoin Cash is a hard fork of Bitcoin with a protocol upgrade to fix on-chain capacity. Bitcoin Cash intends to be a Bitcoin without Segregated Witness (SegWit) as soft fork, where upgrades of the protocol are done mainly through hard forks and without changing the original economic rules of the Bitcoin.  Bitcoin Cash (BCH) is released on 1st August 2017 as an upgraded version of the original Bitcoin Core software. The main upgrade is the increase in the block size limit from 1MB to 8MB. This effectively allows miners on the BCH chain to process up to 8 times more payments per second in comparison to Bitcoin. This makes for faster, cheaper transactions and a much smoother user experience.  Why was Bitcoin Cash Created?  The main objective of Bitcoin Cash is to to bring back the essential qualities of money inherent in the original Bitcoin software. Over the years, these qualities were filtered out of Bitcoin Core and progress was stifled by various people, organizations, and companies involved in Bitcoin protocol development. The result is that Bitcoin Core is currently unusable as money due to increasingly high fees per transactions and transfer times taking hours to complete. This is all because of the 1MB limitation of Bitcoin Core’s block size, causing it unable to accommodate to large number of transactions.  Essentially Bitcoin Cash is a community-activated upgrade (otherwise known as a hard fork) of Bitcoin that increased the block size to 8MB, solving the scaling issues that plague Bitcoin Core today.  Nov 16th 2018: A hashwar resulted in a split between Bitcoin SV and Bitcoin ABC

Bitcoin Cash

Bitcoin Cash (BCH) is generating significant buzz due to the upcoming transformative CashVM (Layla) upgrade in May 2026, positioning it as a highly programmable and scalable blockchain with ultra-low fees. The community is actively discussing its notable year-to-date outperformance against Bitcoin, fueled by a narrative that champions BCH as the true peer-to-peer electronic cash and an increasingly attractive contrarian investment.

Reactive Network is the first parallelized interoperability execution layer, utilising a new form of smart contract we call reactive smart contracts.   Reactive smart contracts are able to react to on-chain events autonomously and execute their own user defined logic to initiate new transactions. This allows a virtually limitless number of use cases to achieve fully decentralized on-chain automation.

Reactive Network

Reactive Network (REACT CRYPTO) is trending due to its pivotal integration as the first project on Ethereum's new EIL testnet and recent launches like automated stop orders for DEXes, positioning its reactive smart contracts as core infrastructure. The community is actively discussing its undervalued technological utility, anticipating substantial long-term growth as the project gains wider recognition in decentralized automation.

Grayscale Investments LLC - Grayscale Bitcoin Trust

Grayscale Bitcoin Trust

Grayscale Bitcoin Trust (GBTC) is trending amid intense debate over Bitcoin's price trajectory, with some investors asserting a bottom is in and anticipating a parabolic rally, while others foresee a prolonged "crypto winter" and further declines. Community sentiment is sharply divided between calls to "buy the dip" and warnings to sell, often noting GBTC's higher expense ratio compared to competitor spot Bitcoin ETFs.

GSI Technology, Inc. engages in the design, development and marketing of memory products primarily for the networking, and telecommunications markets. Its product includes Static Random Access Memory, or SRAM, which incorporated in networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations and network access equipment. It also offers services to the ongoing needs of the military, industrial, test and measurement equipment, automotive and medical markets for SRAMs .The company was founded by Lee-Lean Shu and Robert Yau in March 1995 and is headquartered in Sunnyvale, CA.

GSI Technology Inc

GSI Technology is heavily discussed following claims of impressive performance for its Gemini-II AI chip in edge and defense applications, positioning it as a low-power solution, while simultaneously facing significant allegations of misleading statements and a related class action investigation. The community remains sharply divided over the company's true technological capabilities and market prospects, amidst accusations of pump-and-dump tactics and fundamental flaws.

Lam Research Corp. engages in the design, manufacture, marketing, refurbishment, and provision of semiconductor processing equipment used in the fabrication of integrated circuits. It operates through the following geographical segments: United States, China, Europe, Japan, Korea, Southeast Asia and Taiwan. The company was founded by David K. Lam in 1980 and is headquartered in Fremont, CA.

Lam Research Corp.

Lam Research is trending following its robust earnings report and strong guidance, which has propelled multiple analyst price target upgrades. The community is highly bullish, discussing the company's critical role in the accelerating AI chip and wafer fabrication equipment market, with many anticipating continued upside for the semiconductor leader.

Inseego Corp. engages in the business of communication equipment. Its products include mobile hotspots, industrial gateways and routers, home and enterprise routers, industrial USB modems, and telematics and mobile tracking hardware devices. Its SaaS platforms include Ctrack, an asset tracking and management solution that delivers business intelligence for fleets used in various verticals, including aviation, construction, government, and transport, and Device Management Solutions, a hosted subscription management platform. The company was founded on April 26, 1996 and is headquartered in San Diego, CA.

Inseego Corp

Inseego is trending following its recent earnings, which showed strong Q4 results, positive full-year 2026 guidance, and significant debt reduction, bolstered by new Tier 1 carrier partnerships in the 5G FWA market. However, a cautious Q1 2026 outlook has sparked investor debate between long-term potential and continued short-term volatility.

Nu Holdings Ltd. is a holding company, which engages in the provision of digital banking services. The company was founded by David Vélez Osorno, Cristina Helena Zingaretti Junqueira, and Adam Edward Wible on February 26, 2016 and is headquartered in George Town, Cayman Islands.

Nu Holdings Ltd - Ordinary Shares Class A

Nu Holdings Ltd

Nu Holdings is buzzing after receiving conditional approval for its U.S. bank charter and strong recent financial results, fueling community excitement about its potential for significant expansion beyond its dominant Latin American market. Investors are keenly watching its continued customer growth and AI-first strategy, positioning it as a major competitor to established fintech players.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The company said that its COMP360 drug is the first classic psychedelic to consistently achieve a highly statistically significant result and a clinically meaningful effect.</li><li>Compass said that across both Phase 3 trials to date, COMP360 has demonstrated a generally well-tolerated and safe profile, with no unexpected safety findings.</li><li>The company added that a clinically meaningful reduction in MADRS of more than 25% was observed in a significant number of participants receiving the 25 mg dose in both COMP005 and COMP006 trials.</li></ul>Compass Pathways PLC (CMPS) shares were up more than 23% in Tuesday’s pre-market trade after the company announced that it had successfully achieved the primary endpoint in a Phase 3 clinical trial.Compass announced on Tuesday that its two Phase 3 trials have confirmed a highly differentiated profile for COMP360 for treatment-resistant depression (TRD).<h2 class="st-heading-2">Here Are Compass’ Findings</h2>The company said that its COMP360 drug is the first classic psychedelic to consistently achieve a highly statistically significant result and clinically meaningful effect, with a generally well-tolerated and safe profile.COMP360, a synthetic and proprietary formulation of psilocybin, is designed for TRD. Compass said that across both Phase 3 trials to date, COMP360 has demonstrated a generally well-tolerated and safe profile, with no unexpected safety findings.The company reported that in COMP006, two doses of COMP360 with a dose of 25 mg versus a dose of 1 mg demonstrated a highly statistically significant and clinically meaningful reduction in symptom severity as measured by the Montgomery-Asberg Depression Rating Scale (MADRS.)MADRS is a 10-item clinician-administered tool used to measure the severity of depressive episodes, ranging from 0 to 60. Compass said that the difference in the MADRS score between the 25 mg dose and the 1 mg dose was -3.8.The company added that a clinically meaningful reduction in MADRS of more than 25% was observed in a significant number of participants receiving the 25 mg dose in both COMP005 and COMP006 trials. Compass said that COMP005 participants witnessed a 25% reduction in MADRS, while the reduction stood at 39% among COMP006 participants.The company said that it has sought a meeting with the U.S. Food and Drug Administration (FDA) to discuss a rolling submission and review. It expects to complete a New Drug Application (NDA) submission in the fourth quarter (Q4).“These data strengthen our conviction in the highly differentiated profile for COMP360 and given the urgent need for new treatments in TRD, we are advancing our discussions with the FDA, with the goal of submitting an NDA in Q4 and securing approval,” said Compass CEO Kabir Nath.The company announced in January that the U.S. Food and Drug Administration (FDA) had accepted its Investigational New Drug (IND) application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), allowing the company to begin a late-stage trial.Compass said it is working on making COMP360 ready for commercial launch by the end of the year for TRD as well.<h2 class="st-heading-2">What Does Compass Do?</h2>London-headquartered Compass is a biotechnology company engaged in the development of solutions for mental health conditions through its investigational COMP360 synthetic psilocybin treatment.The company expects to release the 26-week Part B data from its COMP006 trial for TRD in the early third quarter (Q3) this year.<h2 class="st-heading-2">Here’s What Stocktwits Users Think</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/CMPS">Compass</a> trended in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels. The CMPS stock was the second most trending ticker on the platform at the time of writing.One bullish user called the trial results great, while adding that an FDA approval is “likely.”<stembedurl>https://stocktwits.com/Rocketzz/message/645094778</stembedurl>Another user called the results huge news, while saying, “just imagine what different dosing regimens could reveal with this safety profile.”<stembedurl>https://stocktwits.com/VikaDelic/message/645094710</stembedurl><a href="https://stocktwits.com/symbol/CMPS">CMPS stock</a> is down 14% year-to-date, but up 27% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/goldman-sachs-david-solomon-warns-of-shocks-if-deficit-not-controlled/cZR5xtUR4t5">Goldman Sachs CEO David Solomon Warns Of 'Shocks' If Deficit Is Not Brought Under Control And Growth Rate Is Not Brought Up: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

CMPS Stock Rises 23% Pre-Market As Compass Achieves Primary Endpoint In Phase 3 Treatment-Resistant Depression Trial

COMPASS Pathways is currently conducting clinical trials of COMP360, a proprietary synthetic formulation of psilocybin, designed for treatment-resistant depression.

Equity

The company is currently conducting clinical trials of COMP360, a proprietary synthetic formulation of psilocybin, designed for treatment-resistant depression.

<ul class="summary-bullets"><li>For the full fiscal year 2026, the company now expects total revenue in the range of $435 million to $440 million, compared to prior guidance of $425 to $435 million.</li><li>For the current quarter (Q2), the company expects to report revenue of approximately $107 million to $108 million, marking a growth of approximately 16% percent year over year.</li><li>Twist also said that it expects to achieve adjusted EBITDA breakeven in the fourth quarter of fiscal 2026.</li></ul>Shares of Twist Bioscience Corporation (TWST) jumped 8% on Monday after the company hiked its fiscal year 2026 revenue guidance on the heels of a first-quarter (Q1) earnings report that beat Wall Street estimates.<h2 class="st-heading-2">Upbeat Outlook</h2>For the full fiscal year 2026, the company now expects total revenue in the range of $435 million to $440 million, compared to prior guidance of $425 to $435 million, and exceeding an analyst estimate of $430.84 million, according to data from Fiscal AI. &nbsp;For the current quarter (Q2), the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.twistbioscience.com/static-files/af6dbd56-d91e-429e-b337-a8e2675fc255">expects</a> to report revenue of approximately $107 million to $108 million, marking a growth of about 16% percent year over year at the midpoint, and exceeding an estimated $105.08 million.Twist also said that it expects to achieve adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) breakeven in the fourth-quarter of fiscal 2026.<h2 class="st-heading-2">Q1 Numbers</h2>For Q1, the company reported total revenue of $103.7 million, marking a growth of 17%, and above an expected $100.33 million, due to an increase in customers. The company said that it shipped products to about 2,538 customers in Q1 of fiscal 2026, versus approximately 2,376 in the same quarter of the previous fiscal year.Net loss for the quarter came in at $30.5 million, compared to $31.6 million in the corresponding quarter of fiscal 2025.The company also ended the quarter with $198 million in cash, cash equivalents, and short-term investments.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around TWST stock rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume remained at ‘high’ levels.A user applauded the earnings as “solid” progress for investors.<stembedurl>https://www.stocktwits.com/DBRGLong/message/643661292</stembedurl><a href="https://stocktwits.com/symbol/TWST">TWST stock</a> has dropped 16% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/oracle-bond-offering-funding-ai-cloud-infrastructure/cZbgYA1R4ki">ORCL Stock In Focus As Tech Giant Reportedly Launches Bond Offering To Cover Half Of 2026 Funding Needs</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

TWST Shares Rise 8% — What’s Driving The Rally?

Twist Bioscience Corporation hiked its fiscal year 2026 revenue guidance on the heels of a first quarter earnings report that beat Wall Street estimates. 

Cathie Wood, Founder & CEO, Ark Invest, speaks during the second day of the FII PRIORITY Summit

Cathie Wood’s ARK Made Just One Buy Last Session — And It’s A Biotech Stock Up Nearly 30% YTD

ARK doubles down on a CRISPR bet as Intellia Therapeutics’ stock heads for its best week since October.

<ul class="summary-bullets"><li>The company expects to submit a biologics license application for risto-cel by year-end 2026.</li><li>Beam ended 2025 with an estimated $1.25 billion in cash, extending its operating runway into 2029.</li><li>Management will further discuss the developments at the J.P. Morgan Healthcare Conference on January 13.</li></ul>Beam Therapeutics Inc. (BEAM) received a boost from William Blair, which reacted&nbsp;positively to the company’s update on its alignment with the U.S. FDA, citing improved visibility into the data required for regulatory submissions. The firm pointed to progress in Beam’s sickle cell therapy risto-cel and its liver-targeted program BEAM-302.William Blair also noted that both programs’ acceptance into the FDA’s Chemistry, Manufacturing, and Controls Development and Readiness Pilot program could speed development and regulatory review. The brokerage firm reiterated its ‘Outperform’ rating.<h2 class="st-heading-2">Updates on BEAM-302 and Risto-cel</h2>Beam’s update outlined progress across its genetic disease and hematology franchises. The company said it has aligned with the FDA on a potential accelerated approval pathway for BEAM-302 in alpha-1 antitrypsin deficiency (AATD), based on biomarker endpoints. BEAM-302 has shown an in vivo correction of a disease-causing mutation in AATD, and Beam Therapeutics plans to expand patient enrollment to support a future biologics license application (BLA).<a href="https://stocktwits.com/symbol/BEAM">Beam Therapeutics’ stock</a> gained over 28% On Monday afternoon.In hematology, Beam expects to submit a BLA for risto-cel by year-end 2026. The BEACON Phase 1/2 trial is fully enrolled, manufacturing is complete, and recent data continue to show strong efficacy and a predictable manufacturing profile, potentially improving patient experience and treatment center capacity, the company said.Beyond its clinical progress, Beam ended 2025 with an estimated $1.25 billion in cash, extending its operating runway into 2029. This positions the company to fund the anticipated launch of risto-cel and execute pivotal development plans for BEAM-302 without near-term financing risk.Management will further discuss these developments at the J.P. Morgan Healthcare Conference on January 13.<h2 class="st-heading-2">Retail Remains Extremely Bullish</h2>Retail sentiment on Stocktwits remained in the ‘extremely bullish’ zone over the past 24 hours, accompanied by ‘extremely high’ message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/BEAM_jpg_e1fba90ff6.webp" alt="BEAM.jpg" width="925" height="99"><figcaption>&nbsp;</figcaption></figure>One user expects a buyout.<stembedurl>https://stocktwits.com/ReadyMate/message/641529269</stembedurl>Another user expects ‘good times’ ahead.<stembedurl>https://stocktwits.com/Millard_Findlemeyer/message/641539254</stembedurl>Over the past year, the stock has gained around 38%.Read also:<a href="https://stocktwits.com/news-articles/markets/equity/why-did-planet-labs-stock-gain-today/cmUad7cR4Ej">&nbsp;Planet Labs Stock Gained 7% Today — What Is The Swedish Military Deal About?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising chart and reflection of business buildings: stock photo courtesy of Yuichiro Chino via Getty Images

BEAM Stock In Focus As FDA Alignment Wins William Blair’s Praise 

William Blair welcomed the company’s update on its alignment with the U.S. FDA, saying it gives clear visibility into the data needed for regulatory filings.

Biotech ETFs Bounce Back in 2025: Here's Why  

Biotech ETFs rally. IBB, ARKG, SBIO, BBC, CANC and BBP soar as Fed rate cut optimism, FDA approvals, deals and cheaper valuations drive the space in 2025.

Cathie Wood Loves This Under-the-Radar AI Stock. Is It Time for You to Buy Now?

The popular investor poured $366.2 million in the company’s shares to carry out her latest purchase.

Shares of Tempus AI, Inc. were volatile Tuesday, surging to highs last seen in mid-November before paring gains to trade slightly higher.Trading volume was nearly double the daily average as the healthcare tech firm confirmed it will report fourth-quarter and full-year 2024 earnings on Feb. 24, with a conference call at 4:30 p.m. ET.Wall Street expects the company to report an adjusted loss of $0.16 per share on revenue of $203.12 million.Retail sentiment on Stocktwits remained ‘bullish,’ though the score read slightly lower than last week following insider selling.&nbsp;<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/TEM_sentiment_and_message_volume_Feb_11_564e2ba31d.png" alt="TEM sentiment and message volume Feb 11.png" width="1318" height="324"><figcaption>TEM sentiment and message volume Feb 11 as of 11:45 am ET | source: Stocktwits</figcaption></figure>CEO and Chairman Eric Lefkofsky recently sold nearly 240,000 shares between Feb. 5-7, netting over $16.2 million, while CFO Jim Rogers sold 8,712 shares for $588,669, as per SEC filings.Stocktwits users had mixed reactions. One trader noted the stock “gave back most of the pump,” suggesting weak holding interest amid short pressure.&nbsp;Another pointed to a bullish technical setup, predicting a move toward $80.<stembedurl>https://stocktwits.com/phijammaslamma/message/603757859</stembedurl><stembedurl>https://stocktwits.com/CoBear/message/603746559</stembedurl>Tempus AI has gained a lot of&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tem-stock-heads-for-best-rally-in-5-months/chb9WlYR8z">attention</a> since launching an AI-enabled personal health app last month.But it also made headlines after former House Speaker Nancy Pelosi purchased 50 call options in the stock, a trade closely watched by retail investors.Last week, the company announced the completion of its $600 million acquisition of Ambry Genetics.&nbsp;TD Cowen reportedly believes the acquisition strengthens Tempus with a $300-million profitable lab, enhances product offerings, and accelerates its path to positive free cash flow.The research firm, however, thinks Ambry’s slower growth is a concern.Tempus AI stock has surged over 70% since its June 2024 IPO, with its Stocktwits following up nearly 700% in three months.&nbsp;Short interest has also climbed from 3.9% at the start of 2025 to 7.3% by the end of January, per Koyfin data.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration logo of Tempus AI is seen on a smartphone against a screen displaying a trade markets illustration on April 15, 2024 in Krakow, Poland. 

Tempus AI Stock Swings Wildly As Earnings Near, Retail’s Cautiously Optimistic After Insider Sales 

The company has gained a lot of attention since launching an AI-enabled personal health app last month.

Cathie Wood Just Doubled Down on This AI Stock. Should You?

The stock is one of the renowned investor’s top holdings.

Intellia Therapeutics, Inc. shares declined over 5% on Monday morning after Morgan Stanley downgraded the stock to ‘Equal Weight’ from ‘Overweight,’ slashing its price target from $56 to $11.&nbsp;The downgrade and what the brokerage says is a broader lack of catalysts for the year dented retail sentiment, with conversations on Stocktwits turning more skeptical.Morgan Stanley cited a “more measured launch” for nexiguran ziclumeran, Intellia’s lead therapy for transthyretin amyloidosis, a rare and progressive heart disorder.&nbsp;The brokerage also pointed to the company’s recent discontinuation of its NTLA-3001 program for alpha-1 antitrypsin deficiency-associated lung disease, reducing near-term growth prospects.The analyst noted growing competition from non-gene-editing therapies, which could challenge Intellia’s position as a leader in “in vivo” CRISPR editing.&nbsp;Intellia’s approach reportedly delivers CRISPR components directly into the body to modify DNA, bypassing the need to engineer treatments from a patient’s cells.Earlier this month, Intellia announced a 27% workforce reduction and plans to halt&nbsp;the development of NTLA-3001 and some early-stage research programs.The company expects to incur $8 million in restructuring charges in the first quarter but believes the changes, combined with its cash balance of $862 million at the end of the fourth quarter, will extend its cash runway into the first half of 2027.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/NTLA_sentiment_and_message_volume_Jan_27_414be9f90a.png" alt="NTLA sentiment and message volume Jan 27.png" width="1318" height="324"><figcaption>NTLA sentiment and message volume Jan 27 as of 11:40 am ET | source: Stocktwits</figcaption></figure>Retail sentiment on Stocktwits turned more ‘bearish’ following the downgrade.&nbsp;<stembedurl>https://stocktwits.com/KimAntony/message/601612137</stembedurl><stembedurl>https://stocktwits.com/CharlesEscobar/message/601578564</stembedurl><a href="https://stocktwits.com/symbol/NTLA">Intellia’s stock</a> has a high short interest of 21.3% and has lost nearly 60% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Intellia Stock Dips After Morgan Stanley Downgrade, Retail Sentiment Weakens

The brokerage pointed to the company’s recent discontinuation of its NTLA-3001 program for alpha-1 antitrypsin deficiency-associated lung disease, reducing near-term growth prospects.

Shares of Tempus AI climbed more than 5% on Thursday afternoon, poised for their longest winning streak since August 2024.&nbsp;The healthcare technology company has surged from $35 to $53 in just three days, drawing significant retail attention.On Tuesday, Tempus&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tempus-ai-stock-surges-on-ai-enabled-healthcare-app-launch-pelosi-buy/chbdxNURFV">introduced</a> an artificial intelligence-powered healthcare concierge app for patients, sparking optimism about its potential in the growing AI healthcare space.A routine stock trading disclosure revealed former House Speaker Nancy Pelosi purchased 50 call options on Tempus, expiring in January 2026 with a $20 strike price. This added to the speculative excitement surrounding the stock.President Donald Trump’s announcement of “Stargate,” a joint venture with OpenAI, Oracle, and SoftBank to invest billions in domestic AI development, further fueled investor enthusiasm for AI-related stocks like Tempus.While Tempus managed to see a 186% growth in retail followers on Stocktwits since Tuesday, sentiment shifted from ‘extremely bullish’ to ‘bearish’ by Thursday afternoon.&nbsp;The platform saw a spike in pessimistic messages, with users criticizing the frenzy over Pelosi’s involvement and some reporting profit-taking after the stock’s rally.<stembedurl>https://stocktwits.com/WallStreetBetzBoss/message/601130338</stembedurl><stembedurl>https://stocktwits.com/HIGHTABLETRADES/message/601134687</stembedurl><stembedurl>https://stocktwits.com/Harvz90/message/601192109</stembedurl>A regulatory filing from Wednesday night disclosed that Tempus AI founder and CEO Eric Lefkofsky sold 946,084 shares of Tempus between Jan. 15-17.&nbsp;That caused a brief dip in the stock earlier on Thursday, although it rebounded later in the session.Tempus AI has a short interest of 5.5%, according to Koyfin data.Shares of the company have gained over 33% in the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration logo of Tempus AI is seen on a smartphone against a screen displaying a trade markets illustration on April 15, 2024 in Krakow, Poland. (Photo by Dominika Zarzycka/NurPhoto via Getty Images)

Tempus AI Stock Eyes Best Rally In 5 Months Amid Pelosi-Linked Hype, But Retail’s Turning Doubtful Now

A regulatory filing from Wednesday night disclosed that Tempus AI founder and CEO Eric Lefkofsky sold 946,084 shares of Tempus between Jan. 15-17.

ARKG
ARK Investment Management LLC - ARK Genomic Revolution ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest ARKG News

ARKGARK Investment Management LLC - ARK Genomic Revolution ETF